Cantor Fitzgerald Weighs in on MiMedx Group FY2025 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Investment analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for shares of MiMedx Group in a research report issued on Thursday, July 31st. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of $0.25 for the year, up from their previous estimate of $0.24. Cantor Fitzgerald has a “Overweight” rating and a $12.00 price target on the stock. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Cantor Fitzgerald also issued estimates for MiMedx Group’s FY2026 earnings at $0.33 EPS.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.04. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%. The company had revenue of $98.61 million during the quarter, compared to analysts’ expectations of $90.79 million.

Separately, Wall Street Zen raised shares of MiMedx Group from a “hold” rating to a “strong-buy” rating in a research report on Saturday.

MiMedx Group Stock Down 0.4%

MDXG stock opened at $7.16 on Friday. MiMedx Group has a 1-year low of $5.47 and a 1-year high of $10.14. The business’s 50 day simple moving average is $6.44 and its 200 day simple moving average is $7.27. The company has a current ratio of 4.39, a quick ratio of 4.13 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $1.06 billion, a PE ratio of 34.10 and a beta of 1.79.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. First Light Asset Management LLC acquired a new stake in shares of MiMedx Group during the fourth quarter worth $32,168,000. Millennium Management LLC increased its position in MiMedx Group by 93.9% during the first quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock worth $9,355,000 after acquiring an additional 596,016 shares during the period. Meros Investment Management LP raised its stake in MiMedx Group by 107.7% in the 1st quarter. Meros Investment Management LP now owns 820,605 shares of the company’s stock worth $6,237,000 after purchasing an additional 425,531 shares in the last quarter. Norges Bank acquired a new stake in MiMedx Group in the 4th quarter worth about $4,020,000. Finally, JPMorgan Chase & Co. boosted its holdings in MiMedx Group by 133.1% in the 4th quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company’s stock valued at $6,668,000 after purchasing an additional 395,739 shares during the period. 79.15% of the stock is owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.